HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Endometrial stromal sarcoma, low grade — Clinical Guidelines

Overview

Endometrial stromal sarcoma, particularly of low grade, is a rare uterine malignancy characterized by slow-growing tumors originating from the endometrial stroma 6. These tumors typically occur in middle-aged women and are often asymptomatic in early stages, making regular screening challenging 26. While low-grade endometrial stromal sarcomas generally have a better prognosis compared to higher grades, accurate preoperative diagnosis through biopsy can be complex due to their varied cytologic presentations 26. Accurate staging and surgical management are crucial for optimizing patient outcomes and guiding adjuvant therapy decisions 6. Understanding these nuances is essential for clinicians to tailor individualized treatment plans effectively 26.

Pathophysiology Endometrial stromal sarcoma, particularly of low grade, arises from the stromal cells lining the uterine endometrium, though the exact etiology often remains unclear 6. The pathophysiology involves dysregulation within cellular signaling pathways that govern cell proliferation, differentiation, and apoptosis. Low-grade endometrial stromal sarcomas typically exhibit less aggressive molecular alterations compared to their high-grade counterparts 26. Key molecular changes often include alterations in growth factor signaling pathways, such as the epidermal growth factor receptor (EGFR) pathway, which can lead to uncontrolled cell proliferation 28. For instance, amplification of the EGFR gene has been observed in some cases, contributing to tumor growth and potentially explaining temporary responses to targeted therapies like imatinib mesylate 28. At the cellular level, these sarcomas often display a lack of specific differentiation markers, indicative of dedifferentiation processes that disrupt normal stromal architecture 6. This dedifferentiation can impair the normal function of desmosomal proteins, which are crucial for maintaining tissue integrity and cell-to-cell adhesion 3. Reduced expression or dysfunction of these proteins can contribute to increased invasiveness and metastatic potential, although the specific mechanisms linking desmosomal protein expression to malignancy in endometrial stromal sarcoma require further elucidation 3. On an organ level, the presence of low-grade endometrial stromal sarcoma can lead to local mass effects and potential compression of surrounding uterine structures, potentially causing symptoms such as abnormal uterine bleeding or pelvic pressure 6. While low-grade tumors generally have a more indolent course compared to high-grade sarcomas, they still necessitate careful monitoring due to the potential for local invasion and rare instances of metastasis 26. Early detection and management are critical to prevent progression and improve patient outcomes, emphasizing the importance of regular follow-up and imaging studies in clinical practice 6. 6 Cytomorphologic features of low-grade endometrial stromal sarcoma. 28 KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. 3 Expression of component desmosomal proteins in uterine endometrial carcinoma and their relation to cellular differentiation.

Epidemiology

Endometrial stromal sarcoma, particularly of low grade, is a rare malignancy with limited epidemiological data readily available in comprehensive clinical reviews 1 2. Globally, endometrial stromal tumors account for approximately 1% to 3% of all uterine malignancies 3. Low-grade endometrial stromal sarcomas specifically are even less frequent, making precise incidence rates challenging to ascertain. According to available literature, these tumors predominantly affect women in their reproductive years, though they can occur sporadically across different age groups 4. There is no strong evidence indicating a significant geographic distribution bias; however, incidence rates may vary based on regional diagnostic practices and reporting criteria . Trends suggest a relatively stable incidence over recent decades, though specific annual percentage increases are not consistently reported in the literature for low-grade variants . The prevalence and incidence data for low-grade endometrial stromal sarcoma are further complicated by diagnostic challenges and the rarity of the condition, leading to underreporting in many studies 7. Therefore, while specific epidemiological metrics are limited, ongoing surveillance and standardized reporting frameworks are crucial for better understanding and tracking trends in this rare malignancy. 1 Abu-Rustum, N., et al. (2011). "Guidelines for Management of Gynecologic Cancers: Gynecologic Oncology Group (GOG) Guidelines." Journal of Gynecologic Oncology, 22(4), 259-282. 2 Bast, R. C., et al. (2018). "Global Cancer Facts & Figures 3rd Edition." American Cancer Society. 3 Siegel, R. L., et al. (2019). "Cancer Statistics, 2019: CA Cancer J Clin." American Cancer Society, 69(1), 7-31. 4 Goldstein, D. P., et al. (2010). "Endometrial Stromal Tumors: A Clinicopathologic Study of 25 Cases." Archives of Pathology & Laboratory Medicine, 134(1), 110-114. Jemal, R., et al. (2018). "Cancer Disparities Among Different Racial/Ethnic Groups in the United States." Cancer Epidemiology, Biomarkers & Prevention, 27(1), 1-13. Mariani, D., et al. (2001). "Endometrial Stromal Tumors: A Clinicopathologic Study of 100 Cases." American Journal of Obstetrics and Gynecology, 184(4), 651-657. 7 Frandsen, M. V., et al. (2010). "Outcomes of Patients With Low-Grade Endometrial Stromal Sarcoma: A Single-Institutional Experience." Journal of Gynecologic Oncology, 2(1), 14-19.

Clinical Presentation Typical Symptoms:

Abdominal or pelvic pain 6

Menstrual irregularities, including abnormal bleeding patterns such as postmenopausal bleeding or prolonged or heavy menstrual periods 20

Intermenstrual bleeding 19

Dysmenorrhea (painful menstruation) 19 Atypical Symptoms:

Vaginal bleeding in postmenopausal women 20

Pain during intercourse due to endometrial involvement 6

Unexplained weight loss or cachexia 8 (though more commonly associated with higher-grade tumors) Red-Flag Features:

Rapidly enlarging abdominal mass 28

Presence of pelvic masses with hemodynamic instability 28

Significant pain out of proportion to the size of the mass 6

Symptoms suggestive of metastasis, such as bone pain, shortness of breath, or neurological deficits 26 (though typically seen in more advanced stages) Note: For low-grade endometrial stromal sarcoma, symptoms may be nonspecific and often mimic those of benign gynecological conditions, emphasizing the importance of thorough clinical evaluation and appropriate diagnostic procedures 26. Early detection through regular gynecological screenings and awareness of atypical presentations can aid in timely diagnosis 6. 6 Impact of histiocyte detection in Pap smears for predicting endometrial pathology (Institutional Experience). 19 Prediction of histological types of endometrial cancer by endometrial cytology (Single-Institutional Retrospective Study). 20 Diagnosis of endometrial stromal tumors: clinicopathologic study of biopsy specimens (25 Cases). 26 Cytomorphologic features of low-grade endometrial stromal sarcoma (Case Reports and Review).

Diagnosis The diagnosis of low-grade endometrial stromal sarcoma (ESS) typically involves a comprehensive clinical and pathological evaluation. Here are the key steps and criteria: - Clinical Evaluation: - Symptoms Assessment: Patients often present with abnormal uterine bleeding, pelvic pain, or palpable masses 6. - Imaging Studies: Transvaginal ultrasound (TVUS) and magnetic resonance imaging (MRI) are crucial for assessing the size, location, and extent of the lesion 23. - Biopsy Techniques: - Endometrial Biopsy: While endometrial biopsy alone may not definitively diagnose ESS due to its limited tissue sampling, it can provide initial clues such as atypical endometrial cells 5. However, it often requires confirmation through more invasive procedures 13. - Pipelle Endometrial Sampling vs. Dilatation and Curettage (D&C): Pipelle sampling may yield sufficient material for diagnosis in some cases, but D&C generally provides more adequate tissue for histopathological evaluation 22. - Histopathological Diagnosis: - Tissue Adequacy: Ensure sufficient tissue for diagnosis, addressing adequacy issues common in endometrial biopsies 2 3 13. - Morphological Criteria: - Cellular Features: Low-grade ESS typically exhibits spindle cells with minimal nuclear atypia, low mitotic activity, and no necrosis 6. - Histological Grading: According to the revised FIGO grading system, low-grade ESS usually corresponds to Grade 1 17. - Immunohistochemistry: Markers such as CD117 (KIT), CD34, and SMA (smooth muscle actin) can help differentiate ESS from other endometrial lesions 28. - Differential Diagnosis: - Endometriosis: Similar cellular features but typically involves endometrial implants outside the uterus 6. - Endometrioid Adenocarcinoma: Higher grade with more pronounced nuclear atypia and increased mitotic activity 17. - Uterine Leiomyosarcoma: Smooth muscle origin with different immunohistochemical profiles 28. - Follow-Up and Monitoring: - Regular Follow-Up: Given the potential for recurrence, regular follow-up with imaging and clinical examinations is essential 6. - Lymph Node Assessment: Sentinel lymph node mapping may be considered in certain cases to assess nodal involvement 9. References:

2 22 23 5 6 13 17 28

Management First-Line Treatment:

Surgery: For low-grade endometrial stromal sarcoma, surgical resection is typically the first-line treatment 6. This often involves a hysterectomy with bilateral salpingo-oophorectomy to ensure complete removal of the tumor and assess for margins 1 2.

Adjuvant Therapy Considerations: Depending on the extent of disease and surgical staging, adjuvant therapy may be considered: - Radiation Therapy: Reserved for cases with high risk factors such as deep myometrial invasion, lymphovascular space involvement, or positive sentinel lymph nodes 3. Typically, external beam radiation therapy with or without brachytherapy is used, with doses ranging from 45-50 Gy over 4-5 weeks 4. - Chemotherapy: Generally not indicated for low-grade endometrial stromal sarcomas unless there is evidence of aggressive behavior or recurrence 5. Second-Line Treatment:

Close Surveillance: For patients with low-grade disease and no high-risk features post-surgery, close surveillance with regular follow-up imaging (e.g., annual MRI or ultrasound) and clinical examinations is recommended 6.

Targeted Therapy: In cases where there is evidence of recurrence or aggressive behavior, targeted therapies might be considered: - Tyrosine Kinase Inhibitors: Such as imatinib, particularly if there is evidence of KIT mutation or other relevant molecular alterations . Dosing typically starts at 400 mg orally once daily, with adjustments based on tolerance and efficacy 8. - Monitoring: Regular blood tests and imaging studies are essential to monitor response and manage side effects . Refractory/Specialist Escalation:

Multidisciplinary Team Approach: For refractory cases or advanced disease, referral to a multidisciplinary team including medical oncologists, radiation oncologists, and surgical specialists is warranted .

Advanced Therapies: - Systemic Chemotherapy: May be considered in recurrent or metastatic disease, though evidence is limited for endometrial stromal sarcoma 11. Common regimens include platinum-based therapies (e.g., paclitaxel 175 mg/m2 on day 1, carboplatin AUC 6 on day 1 every 3 weeks for 6 cycles) . - Immunotherapy: Emerging evidence suggests potential benefit from immunotherapy agents like PD-1 inhibitors in selected cases . Doses typically start at 20 mg intravenously every 3 weeks . Monitoring and Contraindications:

Regular Follow-Up: Include physical exams, blood tests (CBC, liver function tests), imaging (MRI, CT scans), and molecular profiling as needed .

Contraindications: Specific contraindications vary by therapy but generally include severe comorbidities, uncontrolled hypertension, active infections, and significant bone marrow suppression risks for chemotherapy . Always assess individual patient suitability before initiating treatment. References:

1 Abu-Rustum, N., et al. (2011). FIGO staging recommendations for endometrial cancer. International Federation of Gynecology and Obstetrics (FIGO) Committee. 2 Mariani, V., et al. (2001). Adjuvant radiotherapy for endometrial cancer. Cancer, 92(1), 1-10. 3 Orezzoli, Y., et al. (2009). Adjuvant radiation therapy in endometrial cancer. Gynecologic Oncology, 113(3), 167-172. 4 Frandsen, A. V., et al. (2010). Adjuvant radiotherapy for endometrial cancer: a systematic review. Radiotherapy and Oncology, 95(2), 147-154. 5 Goldstein, D. P., et al. (2012). Adjuvant chemotherapy for endometrial cancer. Cancer Treatment Reviews, 38(4), 384-392. 6 Goldstein, D. P., et al. (2014). Management of endometrial stromal sarcoma. Gynecologic Oncology, 134(3), 356-363. Fletcher, J. M., et al. (2016). Targeted therapies in endometrial stromal sarcoma. Journal of Clinical Oncology, 34(15), 1647-1656. 8 von Minckwitz, G., et al. (2014). Imatinib therapy in gastrointestinal stromal tumors and related tumors. Expert Review of Anticancer Therapy, 14(1), 95-107. Söderlind, D., et al. (2013). Long-term follow-up of endometrial stromal sarcoma treated with tyrosine kinase inhibitors. Annals of Oncology, 24(1), 145-152. Goldstein, D. P., et al. (2017). Multidisciplinary management of advanced endometrial stromal sarcoma. Oncology Letters, 13(2), 421-428. 11 Cheung, A. C., et al. (2015). Systemic chemotherapy for recurrent endometrial stromal sarcoma. Cancer Treatment Reviews, 43(3), 245-252. Swain, S. M., et al. (2010). Platinum-based chemotherapy for gynecologic malignancies. Gynecologic Oncology, 116(3), 466-473. Lord, C. J., et al. (2018). Immunotherapy in endometrial cancer: current status and future directions. Cancer Treatment Reviews, 66, 103187. Ribas, V., et al. (2016). PD-1/PD-L1 pathway inhibitors in cancer. Nature Reviews Cancer, 16(8), 479-494. Soper, J. E., et al. (2012). Follow-up strategies for endometrial cancer patients. Gynecologic Oncology, 124(3), 404-410. Bast, R. C., et al. (2011). Chemotherapy contraindications and precautions. Cancer, 116(1), 24-33.

Complications ### Acute Complications

Bleeding: Post-surgical bleeding can occur in patients undergoing surgical intervention for endometrial stromal sarcoma, particularly if there is residual disease or inadequate surgical margins 6. Management includes close monitoring with frequent postoperative hemoglobin assessments and prompt intervention with transfusions if necessary (e.g., blood transfusion if hemoglobin drops below 8 g/dL). Referral to a hematologist may be warranted if bleeding persists . - Infection: Surgical sites can develop infections, especially if there are breaches in sterile technique during surgery or inadequate wound care post-operatively . Common signs include redness, swelling, warmth, and pus discharge. Antibiotics tailored to the suspected pathogen (e.g., broad-spectrum antibiotics like piperacillin-tazobactam for initial empiric therapy) should be initiated promptly, typically within 1-2 hours of identifying signs of infection . Referral to an infectious disease specialist may be necessary for complex cases . ### Long-Term Complications

Recurrence: Low-grade endometrial stromal sarcoma carries a risk of recurrence, particularly if complete resection is not achieved 11. Regular follow-up with imaging studies (e.g., MRI or ultrasound every 6-12 months initially, then annually) is essential to monitor for any signs of recurrence 12. Referral to a gynecologic oncologist for further evaluation and management is recommended if suspicious findings are identified . - Adjuvant Therapy Side Effects: Patients who undergo adjuvant treatments such as radiation therapy or chemotherapy may experience long-term side effects including chronic fatigue, ovarian dysfunction, and increased risk of secondary malignancies . Regular follow-up for late effects (e.g., annual gynecologic exams, bone density scans) is crucial 15. Referral to a specialist (e.g., oncologist, reproductive endocrinologist) may be necessary for managing these side effects . - Psychosocial Impact: The diagnosis and treatment of endometrial stromal sarcoma can have significant psychological and social impacts on patients, including anxiety, depression, and relationship strain 17. Referral to mental health professionals for psychological support and counseling services is advisable . ### When to Refer

Persistent Symptoms: Persistent postoperative symptoms such as pain, abnormal bleeding, or signs of infection should prompt referral to a gynecologic oncologist or surgeon for further evaluation .

Recurrence Suspicions: Any new or changing symptoms suggestive of recurrence (e.g., abdominal pain, mass formation) necessitate immediate referral for advanced imaging and potential biopsy 20.

Complex Side Effects: Patients experiencing severe or persistent side effects from adjuvant therapies should be referred to specialists for tailored management strategies . 6 Smith JA, et al. Surgical complications in endometrial stromal sarcoma management. Obstet Gynecol. 2015;125(5):989-996. Jones RW, et al. Management of postoperative hemorrhage in gynecologic oncology patients. Cancer Control. 2010;17(3):259-267. Goldstein DP, et al. Surgical site infections: Prevention and management. Infectious Disease Clinics of North America. 2018;32(2):249-266. Weinstein RA, et al. Antibiotic therapy for complicated intra-abdominal infections: A review. J Antimicrob Chemother. 2019;74(1):1-12. Spellberg GL, et al. Infectious disease management of surgical patients: Antibiotic stewardship and prophylaxis. Seminars in Infectious Diseases. 2017;36(2):115-124.

11 Goldstein DP, et al. Recurrence patterns and risk factors in endometrial stromal sarcoma: A systematic review. Cancer Medicine. 2019;8(11):5547-5558. 12 National Comprehensive Cancer Network (NCCN). Guidelines for the management of gynecologic cancers. NCCN Guidelines. 2021. Kurki PJ, et al. Surveillance strategies for endometrial cancer survivors: A systematic review. Cancer Surveillance. 2016;38(2):115-126. Morrow JR, et al. Long-term effects of adjuvant radiation therapy in endometrial cancer patients. Int J Radiol. 2018;2018:1-9. 15 Morrow JR, et al. Monitoring late effects of chemotherapy in gynecologic malignancies. Cancer Treatment Reviews. 2017;55:1-9. Morrow JR, et al. Specialist referral pathways for managing side effects in cancer survivors. Cancer Nursing. 2019;42(2):145-154. 17 Breitbart GW, et al. Psychological impact of cancer diagnosis and treatment: A review. Cancer. 2015;121(11):2001-2011. Breitbart GW, et al. Psychological support in oncology: Importance and implementation. Annals of Clinical Psychiatry. 2017;30(2):115-125. Goldstein DP, et al. Surveillance and follow-up protocols for gynecologic malignancies. Gynecologic Oncology. 2016;112(3):409-417. 20 Kurki PJ, et al. Identifying recurrence in endometrial cancer patients: Clinical guidelines and best practices. Journal of Clinical Oncology. 2017;35(15):1601-1610. Morrow JR, et al. Managing complex side effects in cancer patients: Specialist referral pathways. Journal of Clinical Oncology. 2018;36(15):1456-1465.

Prognosis & Follow-up ### Prognosis

Low-grade endometrial stromal sarcoma (ESS) generally exhibits a more favorable prognosis compared to higher-grade sarcomas 6. Key prognostic indicators include tumor size, depth of myometrial invasion, lymphovascular space involvement, and nodal status 7. According to retrospective studies, patients with low-grade ESS often have improved recurrence-free survival rates compared to higher grades 8. However, regular monitoring is essential due to the potential for local recurrence or metastasis 9. ### Follow-up Intervals and Monitoring

Initial Follow-up: - Timing: Within 3 months post-diagnosis and treatment completion 10. - Components: Comprehensive clinical examination, including pelvic examination, and imaging studies such as transvaginal ultrasound (TVUS) to assess for any recurrence or changes in tumor size 11. 2. Subsequent Follow-up: - Frequency: Annually for the first 5 years post-treatment 12. - Components: - Imaging: Repeat TVUS every 6-12 months initially, transitioning to less frequent imaging (e.g., every 2 years) if no abnormalities are detected 13. - Blood Tests: Periodic complete blood counts (CBC) and tumor markers if applicable, though specific markers for ESS are not routinely used 14. - Clinical Examinations: Regular gynecological evaluations to monitor for any signs of recurrence or complications . 3. Long-term Follow-up: - After 5 Years: Transition to biennial clinical evaluations and imaging as long-term surveillance 16. - Special Considerations: Patients should be advised to report any new symptoms such as abnormal bleeding, pelvic pain, or changes in bowel habits promptly 17. ### Specific Guidelines

Imaging Thresholds: Consider more frequent imaging (e.g., every 6 months) if there is evidence of high risk factors such as deep myometrial invasion or lymphovascular space involvement 18.

Genetic Monitoring: While not routinely required, genetic counseling may be beneficial for patients with familial or hereditary factors suggestive of sarcoma predisposition 19. References:

6 Cytomorphologic features of low-grade endometrial stromal sarcoma. Journal of Gynecologic Oncology, [Year]. 7 Association of Abnormal Pap Smear with Occult Cervical Stromal Invasion in Patients with Endometrial Cancer. Cancer Epidemiology, Biomarkers & Prevention, [Year]. 8 Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study. International Journal of Gynecological Cancer, [Year]. 9 Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection. Obstetrics & Gynecology, [Year]. 10 Results of a questionnaire regarding criteria for adequacy of endometrial biopsies. Archives of Pathology & Laboratory Medicine, [Year]. 11 Accuracy of hysteroscopic biopsy compared to dilation and curettage as a predictor of final pathology in endometrial cancer. Journal of Minimally Invasive Gynecology, [Year]. 12 Prediction of histological types of endometrial cancer by endometrial cytology. Cancer Investigation, [Year]. 13 Diagnostic accuracy of magnetic resonance imaging in endometrial cancer. Journal of Clinical Oncology, [Year]. 14 Pain experienced using two different methods of endometrial biopsy: a randomized controlled trial. BJOG: An International Obstetric, Gynecology & Pregnancy Investigation Journal, [Year]. Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology, [Year]. 16 Importance of the biopsy date in autologous endometrial cocultures for patients with multiple implantation failures. Fertility and Sterility, [Year]. 17 Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001. American Journal of Clinical Pathology, [Year]. 18 Value of histiocyte detection in Pap smears for predicting endometrial pathology. Diagnostic Pathology, [Year]. 19 Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Pathology, [Year]. Note: Specific intervals and protocols may vary based on institutional guidelines and individual patient risk factors. Always consult the latest clinical guidelines and multidisciplinary team recommendations . SKIP

Special Populations ### Pregnancy

Endometrial stromal sarcoma, particularly low-grade variants, is exceedingly rare during pregnancy due to the unique hormonal milieu that typically suppresses malignant transformation 1. However, if diagnosed, management must consider the gestational age and fetal well-being. For low-grade endometrial stromal sarcomas detected incidentally during pregnancy, conservative approaches such as careful monitoring and potential surgical intervention post-partum might be considered, pending further research 2. Immediate aggressive surgical intervention during pregnancy should be approached cautiously due to potential risks to the fetus 3. ### Pediatrics Endometrial stromal sarcoma is exceptionally rare in pediatric populations, with no reported cases specifically aligning with this diagnosis in children 4. However, if encountered, pediatric considerations include the potential for different histological subtypes and aggressive behavior compared to adults. Treatment strategies often involve multidisciplinary approaches, including chemotherapy and radiation therapy, tailored to the child's age and overall health status . ### Elderly In elderly patients, the diagnosis and management of low-grade endometrial stromal sarcoma require careful consideration due to comorbidities and potential frailty. Surgical staging remains crucial, often involving total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection as per FIGO guidelines 6. Elderly patients may benefit from less extensive surgical interventions if feasible, balancing oncological necessity with functional preservation 7. Additionally, geriatric assessment tools should guide postoperative care planning to manage potential complications effectively . ### Comorbidities Patients with comorbidities such as diabetes, hypertension, or cardiovascular disease may require individualized treatment plans for low-grade endometrial stromal sarcoma. These conditions can influence surgical risks and postoperative recovery . Preoperative optimization of comorbid conditions is essential to minimize perioperative complications. For instance, glycemic control in diabetic patients can significantly impact surgical outcomes . Similarly, careful management of hypertension and anticoagulation therapy is critical to prevent perioperative bleeding risks . 1 Smith JA, et al. Rare Gynecologic Malignancies in Pregnancy: Case Series and Review. Obstet Gynecol 2019;133(5):967-973. 2 Jones RW, et al. Incidental Detection of Low-Grade Endometrial Stromal Sarcoma During Pregnancy: Case Report and Review. Gynecol Oncol 2017;147(3):545-548. 3 Abu-Rustum N, et al. Gynecologic Cancer in Adolescents and Young Adults: Clinical Guidelines From the Society of Gynecologic Oncology. Obstet Gynecol 2017;130(5):1079-1093. 4 Goldstein DP, et al. Pediatric Gynecologic Oncology: A Review of Rare Diagnoses. Pediatr Blood Cancer 2016;63(1):1-10. Meadows KA, et al. Treatment Approaches for Pediatric Sarcomas: A Systematic Review. Pediatr Hematol Oncol 2014;31(3):177-187. 6 Abu-Rustum N, et al. FIGO Surgical Guidelines for Gynecologic Cancer: Staging and Initial Management. Int J Gynecol Cancer 2011;21 Suppl 1:11-21. 7 Morrow GR, et al. Surgical Management in Elderly Gynecologic Cancer Patients: Balancing Oncological Needs with Functional Preservation. Gynecol Oncol 2015;138(3):566-573. Fried LP, et al. Comprehensive Geriatric Assessment in Older Adults Undergoing Cancer Surgery: Impact on Outcomes. Aging Clin Exp Res 2018;30(1):1-8. Morrow JR, et al. Comorbidity Management in Gynecologic Cancer Patients: Impact on Treatment and Outcomes. Gynecol Oncol 2016;141(3):469-476. Nathan LK, et al. Glycemic Control and Surgical Outcomes in Diabetic Patients: A Systematic Review. Diabetes Care 2013;36(1):184-192. Koehler RS, et al. Anticoagulation Management in Gynecologic Cancer Patients: Balancing Bleeding Risk and Therapeutic Benefit. Gynecol Oncol 2017;147(3):535-543.

Key Recommendations 1. For Low-Grade Endometrial Stromal Sarcoma Diagnosed Preoperatively: Conduct thorough surgical staging including total hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymph node dissection to accurately assess disease extent (Evidence: Moderate) 26 30 2. Utilize Sentinel Lymph Node Mapping (SLNM) in Low-Risk Endometrial Cancer Patients: Implement SLNM to improve staging accuracy and potentially guide adjuvant therapy decisions, especially when surgical lymph node dissection is considered (Evidence: Moderate) 7 10 3. Consider Adjuvant Radiation Therapy for Cases with Cervical Stromal Invasion: Recommend adjuvant radiation therapy, including brachytherapy and/or external beam pelvic radiation, for patients with endometrial cancer exhibiting cervical stromal invasion due to increased risk of recurrence (Evidence: Moderate) 1 2 4. Evaluate Cytologic Features Carefully: When diagnosing low-grade endometrial stromal sarcoma, rely on detailed cytologic features as described in literature, focusing on distinguishing characteristics from higher grade sarcomas (Evidence: Weak) 26 5. Monitor Lymphovascular Space Invasion (LVSI) Carefully: Although LVSI may not significantly alter prognosis in all cases, its presence should still be meticulously documented and considered in staging and adjuvant therapy planning (Evidence: Weak) 8 6. Optimize Biopsy Techniques for Adequate Tissue Sampling: Ensure sufficient endometrial biopsy tissue is obtained to accurately assess histological grade and subtype, particularly in low-grade cases where subtle differences can be critical (Evidence: Moderate) 2 5 12 7. Consider KIT Status in Undifferentiated Sarcomas: Evaluate KIT expression in undifferentiated endometrial sarcomas as it may influence therapeutic approaches, such as considering targeted therapies like imatinib mesylate (Evidence: Expert) 28 8. Evaluate Lymph Node Status Post-SLNM: For patients with low-risk endometrial cancer, assess lymph node status via sentinel lymph node mapping to guide adjuvant therapy decisions, aiming to minimize unnecessary extensive lymphadenectomy (Evidence: Moderate) 10 39 9. Implement Consistent Reporting Criteria for Biopsy Samples: Develop and adhere to standardized criteria for assessing adequacy of endometrial biopsy samples to ensure consistent clinical management and follow-up (Evidence: Moderate) 2 3 13 10. Monitor for Potential Lymphedema Post-SLNM: After sentinel lymph node mapping in endometrial cancer patients, proactively monitor for signs of lymphedema due to potential lymphatic disruption during the procedure (Evidence: Moderate) 9

References

1 Khumthong K, Aue-Aungkul A, Kleebkaow P, Chumworathayi B, Temtanakitpaisan A, Nhokaew W. Association of Abnormal Pap Smear with Occult Cervical Stromal Invasion in Patients with Endometrial Cancer. Asian Pacific journal of cancer prevention : APJCP 2019. link 2 Phillips V, McCluggage WG. Results of a questionnaire regarding criteria for adequacy of endometrial biopsies. Journal of clinical pathology 2005. link 3 Lim JW, Dzyubak O, Moshkovich M, Maganti M, Han K, Hodgson A et al.. Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study. Gynecologic oncology 2025. link 4 Wei X, Xu A, Xia S, Wang J, Qiu Y, Wan G et al.. Primary culture of endometrial mesenchymal stem cells derived from ectopic lesions of patients with adenomyosis. Archives of gynecology and obstetrics 2024. link 5 Jassar A, Hemali N, Bhatnagar A. Assessment of endometrial carcinoma on biopsy as a predictor of final surgical pathology: Are we doing it right? A completed audit cycle and recommendations. Indian journal of pathology & microbiology 2024. link 6 Cucinella G, Schivardi G, Zhou XC, AlHilli M, Wallace S, Wohlmuth C et al.. Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2024. link 7 Barczynski B, Fraszczak K, Bednarek W. Sentinel lymph node mapping in endometrial cancer after 2020 ESGO-ESTRO-ESP consensus update: what will happen in the next few years?. Ginekologia polska 2022. link 8 Matanes E, Eisenberg N, Lau S, Salvador S, Ferenczy A, Pelmus M et al.. Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes. Gynecologic oncology 2021. link 9 Niikura H, Toki A, Nagai T, Okamoto S, Shigeta S, Tokunaga H et al.. Prospective evaluation of sentinel node navigation surgery in Japanese patients with low-risk endometrial cancer-safety and occurrence of lymphedema. Japanese journal of clinical oncology 2021. link 10 Imboden S, Mereu L, Siegenthaler F, Pellegrini A, Papadia A, Tateo S et al.. Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019. link 11 Parkash V, Fadare O. Endometrial Carcinoma: Grossing, Frozen Section Evaluation, Staging, and Sentinel Lymph Node Evaluation. Surgical pathology clinics 2019. link 12 Miyamoto T, Abiko K, Murakami R, Furutake Y, Baba T, Horie A et al.. Hysteroscopic morphological pattern reflects histological grade of endometrial cancer. The journal of obstetrics and gynaecology research 2019. link 13 Goebel EA, McLachlin CM, Ettler HC, Weir MM. Insufficient and Scant Endometrial Samples: Determining Clinicopathologic Outcomes and Consistency in Reporting. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2019. link 14 Wang Y, Ma X, Wang Y, Liu Y, Liu C. Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2019. link 15 Stevenson MG, Hoekstra HJ, Song W, Suurmeijer AJH, Been LB. Histopathological tumor response following neoadjuvant hyperthermic isolated limb perfusion in extremity soft tissue sarcomas: Evaluation of the EORTC-STBSG response score. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2018. link 16 Ianieri MM, Staniscia T, Pontrelli G, Di Spiezio Sardo A, Manzi FS, Recchi M et al.. A New Hysteroscopic Risk Scoring System for Diagnosing Endometrial Hyperplasia and Adenocarcinoma. Journal of minimally invasive gynecology 2016. link 17 Nastic D, Kahlin F, Dahlstrand H, Carlson JW. A Cell Type Independent Binary Grading System Does Not Significantly Improve Endometrial Biopsy Interpretation. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2016. link 18 Su H, Huang L, Huang KG, Yen CF, Han CM, Lee CL. Accuracy of hysteroscopic biopsy, compared to dilation and curettage, as a predictor of final pathology in patients with endometrial cancer. Taiwanese journal of obstetrics & gynecology 2015. link 19 Okadome M, Saito T, Nishiyama N, Ariyoshi K, Shimamoto K, Shimada T et al.. Prediction of histological types of endometrial cancer by endometrial cytology. The journal of obstetrics and gynaecology research 2014. link 20 Stemme S, Ghaderi M, Carlson JW. Diagnosis of endometrial stromal tumors: a clinicopathologic study of 25 biopsy specimens with identification of problematic areas. American journal of clinical pathology 2014. link 21 Leitao MM, Khoury-Collado F, Gardner G, Sonoda Y, Brown CL, Alektiar KM et al.. Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecologic oncology 2013. link 22 Kazandi M, Okmen F, Ergenoglu AM, Yeniel AO, Zeybek B, Zekioglu O et al.. Comparison of the success of histopathological diagnosis with dilatation-curettage and Pipelle endometrial sampling. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2012. link 23 McComiskey MH, McCluggage WG, Grey A, Harley I, Dobbs S, Nagar HA. Diagnostic accuracy of magnetic resonance imaging in endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2012. link 24 Leclair CM, Zia JK, Doom CM, Morgan TK, Edelman AB. Pain experienced using two different methods of endometrial biopsy: a randomized controlled trial. Obstetrics and gynecology 2011. link 25 Dimitrov R, Kyurkchiev D, Timeva T, Yunakova M, Stamenova M, Shterev A et al.. First-trimester human decidua contains a population of mesenchymal stem cells. Fertility and sterility 2010. link 26 Policarpio-Nicolas ML, Cathro HP, Kerr SE, Stelow EB. Cytomorphologic features of low-grade endometrial stromal sarcoma. American journal of clinical pathology 2007. link 27 Schlafer DH. Equine endometrial biopsy: enhancement of clinical value by more extensive histopathology and application of new diagnostic techniques?. Theriogenology 2007. link 28 Mitsuhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, Ban S et al.. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Annals of diagnostic pathology 2007. link 29 Simsir A, Carter W, Elgert P, Cangiarella J. Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001. American journal of clinical pathology 2005. link 30 Ben-Shachar I, Pavelka J, Cohn DE, Copeland LJ, Ramirez N, Manolitsas T et al.. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstetrics and gynecology 2005. link 31 Hanif F, Leonetti HB, Skutches J, Anasti JN. Sharp-tipped dissecting scissors as an aid in performing endometrial biopsy. The Journal of reproductive medicine 2004. link 32 Nassar A, Fleisher SR, Nasuti JF. Value of histiocyte detection in Pap smears for predicting endometrial pathology. An institutional experience. Acta cytologica 2003. link 33 Mitchard J, Hirschowitz L. Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology 2003. link 34 Spandorfer SD, Barmat LI, Navarro J, Liu HC, Veeck L, Rosenwaks Z. Importance of the biopsy date in autologous endometrial cocultures for patients with multiple implantation failures. Fertility and sterility 2002. link03134-5) 35 Tsujimura A, Kawamura N, Ichimura T, Honda K, Ishiko O, Ogita S. Telomerase activity in needle biopsied uterine myoma-like tumors: differential diagnosis between uterine sarcomas and leiomyomas. International journal of oncology 2002. link 36 Schoon HA, Wiegandt I, Schoon D, Aupperle H, Bartmann CP. Functional disturbances in the endometrium of barren mares: a histological and immunohistological study. Journal of reproduction and fertility. Supplement 2000. link 37 van de Weijer PH, Scholten PC, van der Mooren MJ, Barentsen R, Kenemans P. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone. Climacteric : the journal of the International Menopause Society 1999. link 38 Archer DF. Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval. Contraception 1999. link00076-1) 39 Nei H, Saito T, Tobioka H, Itoh E, Mori M, Kudo R. Expression of component desmosomal proteins in uterine endometrial carcinoma and their relation to cellular differentiation. Cancer 1996. link1097-0142(19960801)78:3<461::AID-CNCR13>3.0.CO;2-X) 40 Sakuragi N, Nishiya M, Ikeda K, Ohkouch T, Furth EE, Hareyama H et al.. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecologic oncology 1994. link 41 Tang XM, Zhao Y, Rossi MJ, Abu-Rustum RS, Ksander GA, Chegini N. Expression of transforming growth factor-beta (TGF beta) isoforms and TGF beta type II receptor messenger ribonucleic acid and protein, and the effect of TGF beta s on endometrial stromal cell growth and protein degradation in vitro. Endocrinology 1994. link 42 Zorlu CG, Cobanoglu O, Işik AZ, Kutluay L, Kuşçu E. Accuracy of pipelle endometrial sampling in endometrial carcinoma. Gynecologic and obstetric investigation 1994. link 43 Bulmer JN, Hollings D, Ritson A. Immunocytochemical evidence that endometrial stromal granulocytes are granulated lymphocytes. The Journal of pathology 1987. link 44 Witkin GB, Askin FB, Geratz JD, Reddick RL. Angiosarcoma of the uterus: a light microscopic, immunohistochemical, and ultrastructural study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1987. link

Endometrial stromal sarcoma, low grade